As a psychiatric provider working with people from all walks of life, I’ve seen how serious mental health conditions, particularly bipolar I disorder (BD-I), can present differently dependi
April was both National Minority Health Month and Counselling Awareness Month, designations that call attention to persistent health disparities among racial and ethnic minorities and lift
China's Luye Pharma has claimed its first FDA approval, getting a green light for Rykindo, an injectable formulation of the antipsychotic risperidone given every two weeks.
BioXcel Therapeutics has claimed its first product approval, getting a green light from the FDA for Igalmi as a treatment for agitation in people with schizophrenia or bipolar disorder.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.